How to Get Tresiba in Florida: Prescriptions, Telehealth, and Pharmacies

What Is Tresiba and Why Florida Patients Request It

Tresiba is a once-daily basal insulin with an ultra-long duration of action, exceeding 42 hours in pharmacodynamic studies, which gives it a flatter and more predictable glucose-lowering profile than insulin glargine U100. Florida has one of the highest rates of diagnosed diabetes in the United States: the CDC reports that approximately 12.4% of Florida adults have diagnosed diabetes, above the national average of 11.6% [1]. That prevalence drives high demand for optimized basal insulin options across the state.

The FDA approved insulin degludec in September 2015 under NDA 203314, covering both type 1 and type 2 diabetes in adults, with a subsequent pediatric label extension for type 1 patients aged one year and older [2]. The prescribing information specifies a starting dose of 10 units once daily for insulin-naive type 2 patients, with titration every three to four days targeting fasting glucose of 80 to 90 mg/dL [2].

The DEVOTE cardiovascular outcomes trial (N=7,637, median follow-up 2.0 years) published in the New England Journal of Medicine in 2017 showed that Tresiba was non-inferior to insulin glargine U100 for three-point MACE (cardiovascular death, nonfatal MI, nonfatal stroke), with a hazard ratio of 0.91 (95% CI 0.78 to 1.06, P<0.001 for non-inferiority) [3]. DEVOTE also reported a 40% lower rate of severe hypoglycemia with Tresiba compared to glargine U100, a finding that matters considerably for Florida's large elderly population [3]. The American Diabetes Association's Standards of Care note that "severe hypoglycemia is associated with increased risk of dementia, cardiovascular events, and mortality," making hypoglycemia reduction clinically meaningful beyond glycemic control alone [4].

Who Can Prescribe Tresiba in Florida

Any Florida-licensed prescriber with DEA registration and the authority to prescribe Schedule III or non-scheduled medications may write a Tresiba prescription. That includes MDs, DOs, advanced practice registered nurses (APRNs) with prescriptive authority, and physician assistants (PAs) operating under a supervisory protocol.

Florida Statute 464.012 grants APRNs prescriptive authority for controlled and non-controlled substances when they hold a current certificate and a protocol with a supervising physician [5]. Insulin is not a controlled substance, so APRNs and PAs working in telehealth or brick-and-mortar endocrinology practices can prescribe Tresiba independently within their scope. The Florida Board of Medicine's telehealth rule (Florida Statute 456.47) explicitly allows prescribing via synchronous audio-video encounters, provided the prescriber establishes a valid patient-provider relationship during that visit [6].

Endocrinologists, internal medicine physicians, and family medicine doctors all routinely prescribe Tresiba in Florida. Board-certified endocrinologists (American Board of Internal Medicine subspecialty) may be more familiar with insulin degludec's titration protocols and the SWITCH trials, but no law restricts prescribing to any single specialty [7].

The HealthRX clinical team uses a three-tier prescriber match for Florida patients requesting Tresiba:

• Tier 1. Telehealth APRN or MD for patients with an existing diabetes diagnosis, stable A1c, and a recent lab panel (within 90 days).
• Tier 2. Telehealth MD or DO with same-day lab order for patients who need baseline kidney function or A1c drawn before titration.
• Tier 3. In-person endocrinology referral for patients with type 1 diabetes on a closed-loop system, recurrent DKA history, or significant renal impairment (eGFR <30 mL/min/1.73m²).

This triage framework reduces unnecessary specialist visits while ensuring that complex patients get the right level of care from the first encounter.

Getting a Tresiba Prescription Through Florida Telehealth

Florida telehealth prescribing for non-controlled substances like insulin degludec is legally straightforward. The prescriber must use a HIPAA-compliant synchronous audio-video platform, collect a medical history, review available records, and document a clinical assessment before issuing a prescription [6]. There is no mandatory in-person visit for insulin prescribing in Florida, distinguishing the state from jurisdictions with stricter telehealth rules.

A typical telehealth workflow for Tresiba in Florida runs as follows. The patient completes an intake questionnaire, uploads recent labs or authorizes a records release, and attends a 20-to-30-minute video visit. If labs are current (A1c within 90 days, basic metabolic panel within 180 days), the prescription can be transmitted electronically to a Florida-licensed retail or mail-order pharmacy the same day. The ADA's 2024 Standards of Care recommend assessing eGFR before initiating or titrating basal insulin to identify patients who may need dose reductions due to reduced renal clearance of insulin [4].

Several national telehealth platforms are licensed to operate in Florida and prescribe Tresiba, including platforms credentialed with the Florida Agency for Health Care Administration (AHCA). Patients should verify that their chosen telehealth provider holds an active Florida medical license or employs Florida-licensed clinicians, verifiable through the Florida Department of Health license lookup tool [8].

Mail-order pharmacies licensed in Florida, including those affiliated with major PBMs, can ship Tresiba with cold-chain packaging anywhere within the state within two to three business days of a verified prescription. A 90-day supply through a mail-order pharmacy typically costs less per unit than a 30-day retail fill when commercial insurance applies its mail-order tier pricing [9].

Labs and Baseline Testing Required Before Starting Tresiba

No single mandatory lab panel is required by Florida law before prescribing insulin degludec. Clinically, however, responsible prescribing follows the ADA's Standards of Care, which recommend a baseline A1c, fasting glucose, complete metabolic panel (including kidney function), and a weight measurement before initiating any new insulin regimen [4].

The FDA prescribing label for Tresiba specifically cautions that dose adjustments may be needed in patients with hepatic impairment or renal impairment, because both conditions alter insulin clearance and hypoglycemia risk [2]. For Florida's older adult population, where chronic kidney disease coexists with type 2 diabetes in roughly 40% of cases according to USRDS data, an eGFR check before starting Tresiba is clinically standard [10].

Recommended baseline labs before a Florida telehealth or in-person Tresiba initiation visit:

1. Hemoglobin A1c (within 90 days)
2. Fasting plasma glucose or glucose log from the past two weeks
3. Basic metabolic panel, including creatinine and eGFR (within 180 days)
4. Body weight and BMI
5. Liver function tests if hepatic disease is suspected

Thyroid function tests are not routinely required before basal insulin but may be ordered if thyroid pathology could explain poor glycemic control. The Endocrine Society's Clinical Practice Guideline on diabetes management notes that "glycemic targets and insulin regimens should be individualized based on patient age, duration of diabetes, comorbidities, and hypoglycemia risk" [11].

Florida Insurance Coverage and Prior Authorization for Tresiba

Prior authorization (PA) is the single largest barrier to Tresiba access in Florida. Most commercial plans operating in Florida, including Blue Cross Blue Shield of Florida (Florida Blue), Aetna, UnitedHealthcare, and Cigna, place Tresiba on Tier 3 or Tier 4 of their formularies and require PA before dispensing [12].

Florida Medicaid (Managed Medical Assistance program) does not cover Tresiba for type 2 diabetes as of 2025. Coverage for type 1 diabetes patients on Florida Medicaid is subject to PA and typically requires documentation of failure or contraindication to insulin glargine biosimilars, which are on Tier 1 or 2 of the Florida Medicaid preferred drug list [13].

A standard PA submission for Tresiba in Florida typically requires:

• A confirmed diabetes diagnosis (ICD-10: E10.x for type 1 or E11.x for type 2)
• Documentation of current A1c and fasting glucose values
• Evidence of an adequate trial (usually 90 days) of a preferred formulary basal insulin such as insulin glargine (Lantus, Basaglar, or Toujeo) or insulin detemir (Levemir)
• Documentation of a clinical reason for switching, such as recurrent hypoglycemia, significant glycemic variability, or patient adherence problems with twice-daily dosing
• Prescriber's NPI and DEA number

The SWITCH 1 and SWITCH 2 trials, published in Diabetes Care, demonstrated that insulin degludec produced significantly lower rates of overall symptomatic hypoglycemia than insulin glargine U100 during the maintenance phase in both type 1 (RR 0.89 to 95% CI 0.85 to 0.94, P<0.001) and type 2 diabetes (RR 0.70 to 95% CI 0.61 to 0.80, P<0.001) in a crossover design [14]. These trial data are the strongest clinical lever in a PA appeal for patients with recurrent hypoglycemia.

If the initial PA is denied, Florida law (Florida Statute 627.4133) gives patients and prescribers the right to a formal appeal and an expedited review within 72 hours for urgent cases [15]. Prescribers should document hypoglycemic episodes with glucose log data or CGM downloads to support the appeal.

Tresiba Costs, Coupons, and Patient Assistance in Florida

Without insurance, a box of five Tresiba FlexTouch pens (3 mL each, 300 units per pen, 1,500 units total) has a list price of approximately $530 to $560 at Florida retail pharmacies as of mid-2025. That translates to roughly $0.35 per unit at a typical daily dose of 20 to 40 units.

Novo Nordisk's My$99Insulin program caps out-of-pocket costs at $99 per 90-day prescription for commercially insured and uninsured patients who meet eligibility criteria [16]. The Novo Nordisk Patient Assistance Program (NovoCare) provides Tresiba at no cost to uninsured patients with household incomes at or below 400% of the federal poverty level [16].

GoodRx and similar discount card platforms list prices between $290 and $380 for the same five-pen box at major Florida pharmacy chains, including CVS, Walgreens, Publix, and Winn-Dixie, depending on zip code. These prices are not insurance and cannot be combined with Medicare Part D [9].

Transferring an Existing Tresiba Prescription to Florida

Patients relocating to Florida with an active Tresiba prescription from another state can transfer it to a Florida-licensed pharmacy under standard pharmacy transfer rules. Florida Statute 465.186 permits pharmacies to accept transferred prescriptions for non-controlled substances, including insulin, from out-of-state pharmacies [17].

The receiving Florida pharmacy contacts the originating pharmacy, verifies the remaining refill authorization, and processes the transfer. For patients whose out-of-state prescription was written by a provider not licensed in Florida, the prescription remains valid for dispensing at a Florida pharmacy as long as it was written by a licensed prescriber in the original state. A new Florida-licensed prescriber is not required for the transfer itself, but any prescription refills after the original supply runs out will need a Florida-licensed prescriber [17].

Mail-order pharmacies operating across state lines and licensed in Florida can also accept prescriptions originally written in other states, provided the prescriber held a valid license in their home state at the time of writing.

503A Compounding Pharmacies and Insulin Degludec in Florida

Florida-licensed 503A compounding pharmacies may compound insulin degludec for individual patient-specific prescriptions. 503A compounding is governed federally by Section 503A of the Federal Food, Drug, and Cosmetic Act and regulated at the state level by the Florida Board of Pharmacy [18].

Compounded insulin degludec is not FDA-approved as a finished product, so it does not carry the same quality assurance as commercially manufactured Tresiba. The FDA's current policy does not include insulin degludec on its list of drugs that may not be compounded (the "negative list"), which means a licensed 503A pharmacy can fill a patient-specific compounded order if a licensed prescriber issues a valid prescription [18].

Reasons a Florida clinician might route a patient to a 503A pharmacy include custom concentration (e.g., U-50 instead of U-100 for pediatric dosing precision), dilution for very small doses in type 1 children, or combination with another agent in a single preparation. Commercial Tresiba is available as U-100 and U-200 formulations from Novo Nordisk; concentrations outside that range require compounding [2].

The Florida Board of Pharmacy requires that all 503A compounding pharmacies maintain USP 797 sterile compounding standards for injectable preparations, including insulin [19]. Patients should verify that their compounding pharmacy holds a current Florida state license and complies with USP 797, which can be checked via the Florida Department of Health license search [8].

Titrating Tresiba After Your First Florida Fill

Starting dose and titration schedule follow the FDA-approved prescribing information and are not altered by Florida-specific rules. For insulin-naive type 2 adults, the label recommends starting at 10 units subcutaneously once daily and adjusting by 2 units every three days based on self-monitored fasting glucose, targeting 80 to 90 mg/dL [2].

For patients converting from once-daily basal insulin (glargine U300, glargine U100, detemir once daily), the conversion is typically unit-for-unit. Patients converting from twice-daily detemir or NPH should use 80% of the total daily NPH dose as the starting Tresiba dose to reduce hypoglycemia risk during the transition [2].

The ADA recommends that patients initiating or titrating basal insulin check fasting glucose daily and contact their prescriber if glucose values fall below 70 mg/dL or exceed 300 mg/dL on two consecutive readings [4]. Florida telehealth platforms typically provide asynchronous messaging between visits so that patients can share glucose logs and receive dose adjustments without scheduling a full video visit. The BRIGHT trial (N=929) compared Tresiba titration algorithms and found that a patient-driven titration algorithm (adjusting 2 units every 3 days to a fasting target of 80 to 90 mg/dL) produced A1c reductions equivalent to a physician-driven algorithm but with fewer clinic contacts, a finding relevant to telehealth efficiency [20].

Continuous glucose monitoring (CGM) is not required to use Tresiba but significantly improves titration safety. Florida Medicaid covers CGM devices for type 1 patients meeting threshold criteria, and Medicare Part B covers CGM for patients on basal insulin who meet frequency-of-testing requirements under the 2023 CMS coverage decision [21].

Hypoglycemia Risk Management for Florida Patients on Tresiba

Hypoglycemia is the primary safety concern with any basal insulin. The DEVOTE trial showed a 40% reduction in confirmed or severe hypoglycemia with Tresiba versus glargine U100 over two years [3]. That difference is most pronounced at night: nocturnal hypoglycemia rates were 53% lower with Tresiba (rate ratio 0.47 to 95% CI 0.38 to 0.59, P<0.001) [3].

Florida's warm climate creates an additional variable: heat and humidity accelerate insulin absorption from subcutaneous depots, which can alter the effective duration and peak of any insulin formulation. Patients should store Tresiba below 86°F (30°C) during the 56-day in-use period and avoid leaving pens in vehicles during Florida summer months when car interior temperatures can exceed 120°F [2]. The FDA label states that Tresiba should not be frozen and should be discarded if it has been frozen [2].

Patients with hypoglycemia unawareness, defined as a loss of the autonomic warning symptoms at glucose values below 54 mg/dL, should use CGM and should inform their Florida prescriber, as this condition may qualify them for PA approval of a CGM device under Florida Medicaid or Medicare guidelines [4].